Head of Medical Affairs
Remix Therapeutics
Head of Medical Affairs
Remix Therapeutics
Biotech firm developing mRNA-degrading therapies
Remix launched with a vision to transform patients’ lives through modulation of RNA processing. Our breakthrough science enables the identification of small molecules that influence the expression of disease‑driving mRNAs and proteins. We focus on diseases of high unmet medical need and are committed to operating with scientific rigor and urgency. With a proprietary in‑house technology platform, we have rapidly generated multiple discovery programs advancing toward the clinic. Remix Therapeutics was recognized as one of BioSpace’s Best Places to Work in Boston 2025 and is backed by leading life sciences investors.
Position Summary:
Remix is seeking a Head of Medical Affairs to provide medical affairs leadership for REM-422 and contribute to the development of future programs across the portfolio. REM-422 is an innovative investigational therapy targeting RNA splicing machinery, with adenoid cystic carcinoma (ACC), a rare salivary gland cancer, as its first clinical indication. With no approved therapy for ACC, this is an opportunity to help shape the medical and treatment landscape for patients with a rare cancer while playing a key role in advancing a novel therapeutic approach.
Reporting directly to the Chief Medical Officer and based at our Watertown, MA headquarters, this individual will play a central role in disease education, scientific leadership, external engagement, evidence generation and trial execution, and interpretation of emerging clinical data. This is the first medical affairs hire at Remix. You will define what the function is, hire the people who follow you, and grow the organization as REM-422 moves toward approval and launch. You will also be the external scientific voice of the company, personally engaged in the field with KOLs and advocacy leaders. The role is global in scope; however, the United States is the initial focus and the first launch market.
Key Responsibilities:
Disease Education and Market Definition
Scientific Leadership and External Engagement
Evidence Generation and Communication
Launch Readiness and Cross-Functional Partnership
Building the Function
Qualifications:
Salary Range
$293,000 - $415,000 USD
This range reflects the expected base salary for this position, plus bonus, equity, and benefits as applicable. Actual salaries may vary based on factors, such as skill, experience, and qualification for the role.
Biotech firm developing mRNA-degrading therapies
Remix Therapeutics develops medicines for rare diseases by using targeted degradation of mRNA with an oral small molecule. Its lead candidate REM 422 degrades messenger RNA to stop production of disease-causing proteins and is in Phase 1 trials for ACC and AML, with FDA Orphan Drug designation. The company funds R&D through grants, partnerships, and eventual commercialization, leveraging collaborations with larger pharma. Its goal is to deliver safe and effective medicines for rare cancers and genetic disorders by advancing REM 422 and expanding its portfolio to address unmet medical needs.
Explore more opportunities at Remix Therapeutics